Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 6.18% is 66% below its 5-year average of 18.01%, near the low end of its 5-year range (6.18%–26.55%).
56.68% below its 12-month average of 14.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 4.74%.
RETURN ON ASSETS (ROA)
6.18%
RETURN ON ASSETS (ROA) AVG TTM
14.27%
RETURN ON ASSETS (ROA) AVG 3Y
15.75%
RETURN ON ASSETS (ROA) AVG 5Y
18.01%
RETURN ON ASSETS (ROA) AVG 10Y
19.38%
RETURN ON ASSETS (ROA) AVG 15Y
-10.84%
RETURN ON ASSETS (ROA) AVG 20Y
-24.45%
CURRENT VS TTM AVG
-56.68%
CURRENT VS 3Y AVG
-60.76%
CURRENT VS 5Y AVG
-65.69%
CURRENT VS 10Y AVG
-68.11%
CURRENT VS 15Y AVG
+157.02%
CURRENT VS 20Y AVG
+125.28%
SECTOR MEDIAN · HEALTHCARE
-23.80%
median of 393 covered companies
CURRENT VS SECTOR MEDIAN
+125.97%
vs the sector median at left
Corcept Therapeutics Incorporated
Market Cap
$13.19B
Return on Assets (ROA)
6.18%
TTM Avg
14.27%
3Y Avg
15.75%
5Y Avg
18.01%
Market Cap
$12.95B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$12.89B
Return on Assets (ROA)
2.01%
TTM Avg
3.05%
3Y Avg
3.16%
5Y Avg
3.84%
Market Cap
$12.52B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
Market Cap
$12.49B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
Market Cap
$14.16B
Return on Assets (ROA)
33.29%
TTM Avg
-24.43%
3Y Avg
-40.18%
5Y Avg
-39.80%
Market Cap
$12.17B
Return on Assets (ROA)
4.91%
TTM Avg
1.34%
3Y Avg
-0.28%
5Y Avg
0.04%
Market Cap
$12.00B
Return on Assets (ROA)
8.33%
TTM Avg
7.48%
3Y Avg
6.38%
5Y Avg
5.99%
Market Cap
$14.64B
Return on Assets (ROA)
-10.75%
TTM Avg
-43.49%
3Y Avg
-42.71%
5Y Avg
-41.26%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | $13.19B | 6.18% | 14.27% | 15.75% | 18.01% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -57.20% | -68.10% | -82.79% | -75.08% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 2.01% | 3.05% | 3.16% | 3.84% |
| Baxter International Inc. (BAX)vs › | $12.52B | -5.37% | -3.64% | -1.62% | 0.47% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 8.13% | 5.32% | 4.08% | 2.47% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 33.29% | -24.43% | -40.18% | -39.80% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 4.91% | 1.34% | -0.28% | 0.04% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 8.33% | 7.48% | 6.38% | 5.99% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -10.75% | -43.49% | -42.71% | -41.26% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 34.50% | 22.59% | 17.42% | 13.40% |
ROA
6.2%
ROE
7.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 11.91% |
| 2024-12-31 | 16.62% |
| 2023-12-31 | 17.08% |
| 2022-12-31 | 17.38% |
| 2021-12-31 | 26.55% |
| 2020-12-31 | 18.54% |
| 2019-12-31 | 22.84% |
| 2018-12-31 | 24.19% |
| 2017-12-31 | 58.55% |
| 2016-12-31 | 11.84% |
| 2015-12-31 | -12.34% |
| 2014-12-31 | -90.62% |
| 2013-12-31 | -72.94% |
| 2012-12-31 | -38.37% |
| 2011-12-31 | -81.22% |
| 2010-12-31 | -103.43% |
| 2009-12-31 | -82.27% |
| 2008-12-31 | -101.45% |
| 2007-12-31 | -65.22% |
| 2006-12-31 | -251.19% |
| 2005-12-31 | -66.63% |
| 2004-12-31 | -32.52% |
| 2003-12-31 | -83.29% |
| 2002-12-31 | -84.90% |
| 2001-12-31 | -30.73% |
